Korro Bio, Inc. (NasdaqCM: KRRO)
Health Care · Biotechnology · US
$9.37
-7.78% today · -79.5% 1Y
Korro Bio, Inc. (NasdaqCM: KRRO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $137.98M and employs 57 people.
Over the last twelve months the share price has lost 79.5%, trading between 5.20 and 55.89.
Tweenvest scores Korro Bio, Inc. across four factors: quality 36/100, value 36/100. Its strongest factor is quality.
KRRO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $137.98M
- Revenue (TTM)
- $2.38M
- P/E
- —
- EPS
- -8.88
- Dividend yield
- —
- Beta (5Y)
- 2.36
- 52-week high
- $55.89
- 52-week low
- $5.20
- Avg volume (3M)
- —
- Shares outstanding
- 14.73M
- Employees
- 57
- Next earnings
- —
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
- ISIN
- US5009461089
- Founded
- 2018
- Listed since
- Oct 3, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Anavex Life Sciences Corp.NasdaqGS: AVXL | $139.97M | $1.51 | +1.34% |
| Voyager Therapeutics, Inc.NasdaqGS: VYGR | $139.87M | $2.27 | -7.35% |
| 3billion, Inc.KOSDAQ: A394800 | $139.66M | ₩5,900.00 | -2.32% |
| NeoImmuneTech, Inc.KOSDAQ: A950220 | $139.14M | ₩1,892.00 | -4.69% |
| Armata Pharmaceuticals, Inc.NYSEAM: ARMP | $134.97M | $3.58 | -1.38% |
| Innate Pharma S.A.ENXTPA: IPH | $134.19M | €1.28 | -1.54% |
| NIBEC Co., Ltd.KOSDAQ: A138610 | $132.33M | ₩15,650.00 | -2.07% |
| StemCyte International, Ltd.TWSE: 4178 | $132.32M | NT$19.60 | +8.89% |
Figures last refreshed Oct 11, 2026.